Eagle Capital Growth Fund, Inc. (GRF) Dividend History

Dividend Yield: 6.53%

Dividend Frequency: Annually

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
December 19, 2024	$0.68	11/29/2024	11/29/2024
December 15, 2023	$0.35	11/22/2023	11/24/2023
December 14, 2022	$0.37	11/17/2022	11/18/2022
December 23, 2021	$0.97	11/18/2021	11/19/2021
December 22, 2020	$0.55	12/03/2020	12/04/2020
December 26, 2019	$0.07	11/21/2019	11/22/2019
December 26, 2019	$0.49	11/21/2019	11/22/2019
December 28, 2018	$0.45	11/21/2018	11/23/2018
December 28, 2018	$0.08	11/21/2018	11/23/2018
December 28, 2017	$0.51	11/22/2017	11/24/2017
December 28, 2016	$0.10	11/21/2016	11/23/2016
December 28, 2016	$1.09	11/21/2016	11/23/2016
December 28, 2015	$0.18	11/19/2015	11/23/2015
December 28, 2015	$0.32	11/19/2015	11/23/2015
December 24, 2014	$0.35	12/10/2014	12/12/2014
December 24, 2014	$0.02	12/10/2014	12/12/2014
December 27, 2013	$0.14	12/11/2013	12/13/2013
December 27, 2013	$0.88	12/11/2013	12/13/2013
December 28, 2012	$0.04	12/13/2012	12/17/2012
December 28, 2012	$0.32	12/13/2012	12/17/2012
December 27, 2011	$0.10	12/14/2011	12/16/2011
December 27, 2011	$0.95	12/14/2011	12/16/2011
December 29, 2010	$0.28	12/15/2010	12/17/2010
December 28, 2009	$0.05	12/09/2009	12/11/2009
December 26, 2008	$0.26	12/10/2008	12/12/2008
December 26, 2008	$0.05	12/10/2008	12/12/2008
December 26, 2008	$0.04	12/10/2008	12/12/2008

Dividends Summary

Eagle Capital Growth Fund, Inc. has issued 27 dividend payments over the past 16 years
The most recent dividend was paid 217 days ago, on December 19, 2024
The first recorded dividend was paid on December 26, 2008
The highest dividend payout was $1.09 per share
The average dividend over this 16 year span is $0.36 per share
Eagle Capital Growth Fund, Inc. has increased its dividend payments by 1566.67% since 2008

Company News

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo® during the next seven years, following recent Food and Drug Administration (FDA) approval to treat primary immunodeficiencies (PID).

GlobeNewswire Inc.
Grifols shares rebound after KPMG greenlights accounts

The Barcelona company has seen share price collapse since publication of a report from Gotham City Research in January

MarketWatch
Income Portfolio - 38 CEFs Worth Exploring

Dividend-paying CEFs with positive NAV since inception now number only 38, which is less than 10%. Click here for a detailed analysis.

Seeking Alpha

Featured Companies: ADX BME BST BSTZ BUI CET EEA EMF ETO EVT FUND GAM GDV GGZ GRX HQH HQL IFN IIF MCI MPV MXF NUW PEO QQQX RMT RVT SOR STEW STK SWZ THQ TY UTF UTG

Page data last updated 07/24/2025 02:35:28 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included